Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04442334
Other study ID # 08759
Secondary ID 634413777377
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2015
Est. completion date December 31, 2030

Study information

Verified date January 2023
Source Newcastle University
Contact Quentin M Anstee, MBBS, PhD
Phone +44(0)191 20 87012
Email quentin.anstee@ncl.ac.uk
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. The ultimate goals are to better understand the drivers of interpatient variation in disease pathophysiology and severity and to utilise this information to develop and validate biomarkers that, singly or in combination, enable detection and monitoring of disease progression and/or from NAFL through NASH to fibrosis and cirrhosis.


Description:

The European NAFLD Registry is a major international collaboration between clinical academics at leading universities across Europe, initially established with funding from the European Association for the Study of the Liver and through the EU FP7, H2020 and IMI2 schemes to the projects FLIP (Fatty Liver Inhibition of Progression), EPoS (Elucidating Pathways of Steatohepatitis) and LITMUS (Liver Investigation: Testing marker Utility in Steatohepatitis). The Registry is a non-interventional, observational study collecting cross-sectional and longitudinal clinical data (including clinical biochemistry/haematology, liver histology, comorbidities, prescribed medication and imaging data) and linked biological samples (Blood [Serum, Plasma], Liver Tissue, Urine, Stool) from prospectively recruited patients with NAFLD. Its purpose is to support clinical and translational research into disease pathophysiology (through development of comprehensive genetic, epigenetic, transcriptomic, metabolomic, proteomic and metagenomic datasets) and biomarker development/validation. It supports collaborative discovery science and serves as the basis for a broad international project to discover and validate biomarkers for NAFLD and associated medical conditions (LITMUS). Out-with the current study, following separate ethical approval and after separate consent, patients who have agreed to join the European NAFLD Registry may also agree to participate in a number of nested sub-studies with bi-directional sharing of data. These include the LITMUS Imaging Study, which will acquire additional imaging data across a range of modalities including, amongst others, MR-PDFF and MR-Elastography. The Registry population comprises adult patients (aged ≥18 years) with risk factors for non-alcoholic fatty liver disease (NAFLD) prospectively recruited primarily in hepatology and diabetology clinics and/or bariatric surgery units at centres across Europe. After receiving informed consent, patients will be assigned a unique study identifier (which will be used to identify all data and samples collected) which will allow all information to be recorded in a link-anonymised form.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date December 31, 2030
Est. primary completion date December 31, 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Age =18 years. 2. Clinically suspected NAFLD based on any of: 1. Patient with historical liver biopsy providing histological evidence of NAFLD or, 2. Patient undergoing liver biopsy for suspected NAFLD with biochemical and/or radiological findings consistent with NAFLD or, 3. Patient with radiological evidence of cirrhosis (in absence of an alternative aetiology) plus presence of =2 features indicative of the 'metabolic syndrome': - Increased waist circumference by ethnically adjusted criteria (e.g. Europid male/female =94cm/80cm) or overweight/obese (BMI =25); - Raised fasting glucose =100 mg/dL [5.6 mmol/L], HbA1c =48mmol/mol (6.5%) or previously diagnosed insulin resistance/type 2 diabetes mellitus (or on treatment); - Dyslipidaemia (fasting TG level =150 mg/dL [1.7 mmol/L]; or fasting HDL <40 mg/dL [1.03 mmol/L] in males and <50 mg/dL [1.29 mmol/L] in females; or on treatment); - Hypertension (systolic BP =130 or diastolic BP =85 mmHg, or on treatment). 3. Average alcohol consumption less than 21/14 units/week (males/females) in preceding 6 months and no history of sustained excessive consumption of alcohol in past 5 years. Exclusion Criteria 1. Refusal or inability (lack of capacity) to give informed consent. 2. Average alcohol ingestion greater than approximately 21/14 units/week (males/females) in preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years. 3. History or presence of Type 1 diabetes mellitus. 4. Presence of any other form of chronic liver disease except NAFLD. 5. Recent (within 12 months) or concomitant use of agents known to cause hepatic steatosis (long-term systemic corticosteroids [>10 days], amiodarone, methotrexate, tamoxifen, tetracycline, high dose oestrogens, valproic acid). 6. Any contra-indication to liver biopsy. 7. Recent (within 3 months) change in dose/regimen or introduction of Vitamin E (at a dose =400 IU/day), betaine, s-adenosyl methionine, ursodeoxycholic acid, silymarin or pentoxifylline. 8. Non-English speaking/unable to access an interpreter. Due to the nature of the study, English language or access to a relevant interpreter is a necessary criterion to ensure lifestyle (diet and exercise) and symptom data are collated. 9. Patients not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study.

Study Design


Locations

Country Name City State
Belgium Universitair Ziekenhuis Antwerpen Antwerp
Finland Helsinki University Hospital Helsinki
France Le Centre de Recherche Clinique (CRC) du CHU d'Angers Angers
France Institut ICAN - Institute of Cardiometabolism And Nutrition Hôpital de la Pitié Salpêtrière Paris
Germany UNIVERSITÄTSKLINIKUM der RWTH Aachen Aachen
Germany Charité University Hospital Berlin Berlin
Germany Universitätsklinikum Freiburg Freiburg
Germany UNIVERSITÄTSMEDIZIN der Johannes Gutenberg Universität Mainz Mainz
Germany Universitätsklinikums Würzburg Würzburg
Greece Laiko General Hospital of Athens Athens
Italy Polytechnic University of Marche Ancona
Italy Università degli Studi Milano Milan
Italy Università di Palermo Palermo
Italy Università Cattolica del Sacro Cuore Rome
Italy Department of Medical Sciences University of Torino Turin
Netherlands Amsterdam UMC Amsterdam
Portugal Hospital de Santa Maria Lisboa
Spain Vall d'Hebron University Hospital Barcelona
Spain Biodonostia Health Research Institute Donostia
Spain Puerta de Hierro University Hospital Majadahonda
Spain Marqués de Valdecilla University Hospital Santander
Spain Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital Sevilla
Spain HU Clínico de Valladolid Valladolid
Sweden Karolinska Universitetssjukhuset Huddinge
Sweden Linköping University Hospital Linköping
Switzerland Inselspital, University Hospital Bern
United Kingdom University Hospitals Birmingham Nhs Foundation Trust Birmingham
United Kingdom Addenbrooke'S Hospital Cambridge
United Kingdom Queen Elizabeth Hospital Gateshead
United Kingdom Hull Royal Infirmary Hull
United Kingdom Royal London Hospital, Barts Health NHS Trust London
United Kingdom St George's University Hospitals London
United Kingdom The Newcastle Upon Tyne Hospitals Nhs Foundation Trust Newcastle-upon Tyne
United Kingdom Queen'S Medical Centre Nottingham
United Kingdom Oxford University Hospitals Nhs Foundation Trust Oxford
United Kingdom Derriford Hospital Plymouth
United Kingdom Queen Alexandra Hospital Portsmouth

Sponsors (27)

Lead Sponsor Collaborator
Newcastle University Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Assistance Publique - Hôpitaux de Paris, Catholic University of the Sacred Heart, Institute of Cardiometabolism and Nutrition, France, Linkoeping University, Medical University of Vienna, National and Kapodistrian University of Athens, Newcastle-upon-Tyne Hospitals NHS Trust, Örebro University, Sweden, RWTH Aachen University, UMC Utrecht, University Hospital, Antwerp, University Medical Center Mainz, University of Angers, University of Bern, University of Birmingham, University of Cambridge, University of Florence, University of Helsinki, University of Lisbon, University of Milan, University of Nottingham, University of Oxford, University of Palermo, University of Turin, Italy, Wuerzburg University Hospital

Countries where clinical trial is conducted

Belgium,  Finland,  France,  Germany,  Greece,  Italy,  Netherlands,  Portugal,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Detailed Characterisation of the NAFLD Patient Phenotype Prospective patient recruitment and collection of cross-sectional clinical data is undertaken (including clinical biochemistry/haematology, liver histology, comorbidities, prescribed medication and imaging data).These data will be used to determine number of participants exhibiting specific features of NAFLD/NASH disease severity at enrolment including: histological grade of disease and fibrosis stage (assessed using the well validated NASH Clinical Research Network "NAFLD Activity Score" [NAS] and the FLIP "Steatosis - Activity - Fibrosis" [SAF] systems), frequency of common metabolic comorbidities (eg type 2 diabetes mellitus, dyslipidaemia, cardiovascular disease), and associated changes in clinical biochemistry/haematology/imaging parameters. Biological samples to support clinical and translational research into disease pathophysiology (e.g. genetic, epigenetic, transcriptomic, metabolomic, proteomic and metagenomic datasets) and biomarker development/validation will be collected. 1 day
Secondary Disease Natural History Longitudinal follow-up of patients with NAFLD by annual review to characterise disease natural history and determine number of participants experiencing clinically significant events including the occurrence and timing of incident comorbidities and key target conditions of interest such as:
Death (cause of death)
Major Adverse Cardiovascular Events (MACE)
Hepatic (e.g. diagnosis of cirrhosis, hepatic decompensation, hepatocellular carcinoma, transplantation)
Other (diagnosis of extra-hepatic malignancy/emergency hospitalisation)
Routine clinical data generated as part of standard care will be collected annually. Clinical parameters assessed for changes indicative of alteration in disease state during follow-up include: clinical biochemistry/haematology, liver histology, comorbidities, prescribed medication and imaging data. Biological samples to support translational research into disease pathophysiology and biomarker development/validation will also be collected.
Through to study completion, an average of 5 years
Secondary Lifestyle factors: Dietary Habits Cross-sectional and longitudinal study of dietary habits in patients with NAFLD using: Mediterranean Diet Score. Through study completion, an average of 5 years
Secondary Lifestyle factors: Activity/Exercise Cross-sectional and longitudinal study of lifestyle factors (e.g. activity/sedentary behaviour/exercise levels) in patients with NAFLD using: International Physical Activity Questionnaire (IPAQ). Through study completion, an average of 5 years
Secondary Health Related Quality of Life: CLDQ Cross-sectional and longitudinal collection of standardised data on HRQOL and symptom burden in patients with NAFLD using Patient Reported Outcome Measure (PROM): Chronic Liver Disease Questionnaire for NAFLD NASH (CLDQ NAFLD-NASH). Through study completion, an average of 5 years
Secondary Health Related Quality of Life: EQ5D5L Cross-sectional and longitudinal collection of standardised data on HRQOL and symptom burden in patients with NAFLD using Patient Reported Outcome Measure (PROM): EQ-5D-5L Health Through study completion, an average of 5 years
Secondary Health Related Quality of Life: NASH-CHECK Cross-sectional and longitudinal collection of standardised data on HRQOL and symptom burden in patients with NAFLD using Patient Reported Outcome Measure (PROM): NASH-CHECK. Through study completion, an average of 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2